Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298092 | 0.99 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2659079 | 0.89 | GABRG2 (0.58) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6294045 | 0.87 | GABRG2 (0.72) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2658601 | 0.84 | GABRG2 (0.71) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL2658938 | 0.83 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL340381 | 0.82 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6292893 | 0.81 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6769111 | 0.80 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6292932 | 0.78 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6292580 | 0.78 | GABRG2 (0.65) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872720-B2 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-03-29 | — | — | US | claimed |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-27 | — | — | US | claimed |
| US-6872720-B2 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-03-29 | — | — | US | disclosed |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA4 | GABRG2 15/4885GABRB3 7/4885GABRA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.